Skip to content
“Initial weight loss is just the first chapter,” said Mia de Graaf, Deputy Executive Health Editor at Business Insider, “but the real challenge and […]
BIO 2025: How weight loss drugs are disrupting chronic disease Read More »
When experts discussed clinical uses of psychedelics two years ago at the 2023 Biotechnology Innovation Organization (BIO) International Convention, there was some interest in
BIO 2025: Psychedelics go mainstream – what’s next? Read More »
For most of her life, the only things coming out of left field for Kristin Smedley were fly balls, but with the birth of
Mother inspired to support solutions for her boys’ blindness Read More »
As drug makers work to develop safe, effective gene therapies, their progress can be slowed when they challenge the limits of established regulatory guidance
The federal government’s program that provides seed funding to support research by biotech startups provides much more than money, said program officials and small
BIO 2025: Federal seed funding also comes with valuable advice Read More »
Prostate cancer is the most common solid cancer among men, with 1 in 8 men being diagnosed in their lifetime and 1 in 44
Three questions men can ask about prostate cancer Read More »
As antimicrobial resistance (AMR) continues to threaten global public health, its impact on cancer patients is a growing, often overlooked crisis. Patients with cancer
BIO 2025: The urgent need to address AMR and cancer Read More »
Patents enable the innovation that produces new lifesaving treatments while ensuring a competitive market, the top IP expert for the Biotechnology Innovation Organization (BIO)
BIO expert explains patents at DOJ and FTC listening session Read More »
The exciting new developments we’re seeing in biotechnology must be supported by equally innovative policy, according to Fritz Bittenbender, the new Chair of the
A conversation with Fritz Bittenbender, new BIO Board Chair Read More »
Even if they aren’t making revenue, small biotechs can face onerous reporting requirements that cost $1 million or more, cutting into the firms’ ability
Onerous reporting requirements crushing small biotechs, BIO Board member testifies Read More »
